Search - tctmd.com

Displaying 21 - 37 of 37

Sort: Relevancy | Date

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

Caitlin E. Cox

January 01, 2019

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

Advertisement

Recurrent Events Common Among Young Patients With CAD

TCTMD’s Top 10 Most Popular Stories for September 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

TCTMD’s Top 10 Most Popular Stories for December 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

TCTMD’s Top 10 Most Popular Stories for December 2017

TCTMD’s Top 10 Most Popular Stories for November 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Discussion Highlights Merits, Limitations of Small Trials

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content